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Abstract
Despite existing evidence-based practice guidelines for the management of biliary acute pancreatitis (AP), the clinical 
compliance with recommendations is overall poor. Studies in this field have identified significant discrepancies between 
evidence-based recommendations and daily clinical practice. The most commonly reported gaps between clinical practice 
and AP guidelines include the indications for CT scan, need and timing of artificial nutritional support, indications for anti-
biotics, and surgical/endoscopic management of biliary AP. The MANCTRA-1 (coMpliAnce with evideNce-based cliniCal 
guidelines in the managemenT of acute biliaRy pancreAtitis) study is aiming to identify the areas for quality improvement 
that will require new implementation strategies. The study primary objective is to evaluate which items of the current AP 
guidelines are commonly disregarded and if they correlate with negative clinical outcomes according to the different clinical 
presentations of the disease. We attempt to summarize the main areas of sub-optimal care due to the lack of compliance with 
current guidelines to provide the basis for introducing a number of bundles in AP patients’ management to be implemented 
during the next years. The MANCTRA-1 study is an international multicenter, retrospective cohort study with the purpose 
to assess the outcomes of patients admitted to hospital with a diagnosis of biliary AP and the compliance of surgeons world-
wide to the most up-to-dated international guidelines on biliary AP. ClinicalTrials.Gov ID Number: NCT04747990, Date: 
February 23, 2021. Protocol Version V2.2.
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Abbreviations
AP  Acute pancreatitis
IAP  International Association of Pancreatology
APA  American Pancreatic Association (APA)
ANP  Acute necrotizing pancreatitis
RCTs  Randomized-controlled trials
Covid-19  Coronavirus disease 2019
ERCP  Endoscopic retrograde 
cholangiopancreatography
CRP  C-reactive protein
CT  Computed tomography
MRCP  Magnetic resonance cholangiopancreatography
WON  Walled-off necrosis
CRF  Case report form
HPB  Hepato-pancreato-biliary
Introduction
Acute pancreatitis (AP) is an inflammatory disease of the 
pancreas, most commonly caused by gallstones or excessive 
alcohol use. The incidence of AP ranges globally from 5 to 
30 cases per 100.000 inhabitants/year, and there is evidence 
that the incidence has increased in recent years. The overall 
case-fatality rate for AP is roughly 5%, and it is expectedly 
higher for more severe stages of the disease [1, 2]. In most 
cases (80%), the outcome of AP is rapidly favorable [3]. 
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However, acute necrotizing pancreatitis (ANP) may develop 
in up to 20% of cases and is associated with significant rates 
of early organ failure (38%), needing some surgical/endo-
scopic intervention (38%), and death (15%) [4].
Infection of pancreatic necrosis is the predominant driver 
of sustained morbidity and late mortality in patients with 
severe AP. The subset of patients with ANP may face a 
complicated and prolonged clinical course with an associ-
ated mortality of up to 30% if an infection develops in the 
necrotic collection [5]. Optimal management of patients with 
pancreatic necrosis requires a multidisciplinary approach, 
and ad-hoc guidelines for this specific subgroup of patients 
have been recently released [6]. Although antibiotic prophy-
laxis may prevent or reduce the risk of necrosis colonization, 
the results of randomized-controlled trials (RCTs) evaluat-
ing this approach and meta-analyses do not support routine 
use of antibiotic prophylaxis in these patients [7]. However, 
several global overviews assessing reports from across the 
world of the use of antibiotics in prophylaxis in AP have 
shown a wide diffusion of such behavior [8].
In 2020, the spread of the virus COVID-19 represented 
a pandemic, which also profoundly impacted the surgical 
community [9–11]. The constant increase in the number of 
patients requiring treatment became a massive challenge for 
the healthcare systems of many involved countries. In an 
emergency situation, resources must be focused and used 
rationally to handle the pandemic as well as to continue han-
dling the pre-existing diseases. In this context, most surgi-
cal departments were obliged to re-schedule their activity, 
giving priority to urgent/emergent surgical cases and non-
deferrable oncological cases. The outbreak of the COVID-
19 pandemic could have influenced in many ways the daily 
clinical practice for patients with biliary AP, leading to a 
failure in adherence to the recommendations provided by 
the guidelines, especially those regarding the early and 
definitive treatment with cholecystectomy or endoscopic 
retrograde cholangiopancreatography (ERCP) and sphinc-
terotomy. First of all, the recommendation to postpone all 
non-urgent endoscopic procedures during the peak of the 
pandemic; second, the recommendation to conservatively 
treat inflammatory conditions such as acute cholecystitis and 
acute appendicitis wherever possible.
Several scientific societies have issued practice guidelines 
and consensus documents over the past decades to guide 
physicians and surgeons in managing AP [12–19]. The 
main topics of such guidelines included diagnosis, use of 
prophylactic antibiotics, management in the intensive-care 
unit, surgical and operative management, and open abdomen 
management.
The rationale for the study
It is commonly thought that clinical guidelines would help 
to decrease inappropriate variation of practice, as well as 
that they provide a rational basis for referral, and they 
would help to reduce uncertainty in the management of 
certain conditions. Clinical guidelines also provide a basis 
for continuing medical education and can improve control 
of healthcare costs. However, the value of national and/or 
international guidelines is mostly dependent on a strategy 
for their implementation.
Even though the contemporary literature includes sev-
eral studies on the management of biliary AP, reports 
about the real-world implementation of evidence-based 
recommendations coming from AP guidelines are scant. 
As the way in which biliary AP is managed in the early 
stages could impact the progression of the disease and sub-
sequent events, it would be important to investigate how 
recommendations from guidelines are perceived in the real 
world by clinicians worldwide. Numerous Clinical Audit 
about biliary AP has been performed in Italy, Germany, 
France, and England [20–23], revealing discrepancies in 
AP management and lack of compliance to guidelines 
[20, 22–26]. The most commonly reported gaps between 
clinical practice and guidelines include the indications for 
CT scan, need and timing of artificial nutritional support, 
indications for antibiotics, and surgical/endoscopic man-
agement of biliary AP. Less than 15% of the respondents 
stated that they strictly followed all recommendations 
included in the guidelines in Germany [22], and 25.8% 
of patients did not receive definitive treatment for biliary 
AP within 1 year in the UK [27]. A recent study from 
Singapore aiming to review the clinical management of 
patients with AP in an HPB referral center in the light 
of assessing the compliance to the 2013 International 
Association of Pancreatology (IAP)/American Pancre-
atic Association (APA) and the 2015 Japanese guidelines 
found that only 50% of patients received Ringer lactate 
for initial fluid resuscitation, 38.7% received antibiotics as 
prophylaxis, 21.4% of patients with severe AP had early 
enteral nutrition, and only 21.4% patients with biliary AP 
had index admission cholecystectomy despite the recom-
mendations [28]. In another recent study by a Canadian 
group, only 25% of patients with gallstones AP underwent 
a cholecystectomy on the same admission. Furthermore, 
only one-quarter of patients in whom an index admission 
cholecystectomy was not possible underwent ERCP with 
sphincterotomy, and only one-third of patients with gall-
stones AP and an imaging-confirmed obstructed common 
bile duct had an ERCP and sphincterotomy [29]. Slow 
implementation of the guidelines on early cholecystec-
tomy has also been reported in a Danish survey seeking 
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compliance with the recommendations of the national ref-
erence program for the treatment of patients with gallstone 
disease [30], and a similar lack of compliance with guide-
lines was found in Italy, mainly regarding indications for 
endoscopic and surgical management [31]. Conversely, a 
recent study from Sweden found that 80% of patients with 
biliary AP underwent definitive treatment during their first 
attack (68% cholecystectomy, 17% ERCP and sphincter-
otomy, 15% both interventions) [32].
The MANCTRA-1 (coMpliAnce with evideNce-based 
cliniCal guidelines in the managemenT of acute biliaRy 
pancreAtitis) study can identify a number of areas for 
quality improvement that will require new implementation 
strategies. We aim to summarize the main areas of sub-
optimal care due to the lack of compliance with current 
guidelines and the possible correlation between non-com-
pliance with guidelines and adverse outcomes to finally 
provide the basis for introducing a number of bundles in 
the management of patients with AP, to be implemented 
during the next years.
Methods
The MANCTRA-1 study protocol is designed according to 
the SPIRIT 2013 explanation and elaboration: guidance for 
protocols of clinical trials [33]. The MANCTRA Steering 
Committee, composed of delegates from the World Soci-
ety of Emergency Surgery (WSES), the Association of 
Italian Surgeons in Europe (ACIE), the Italian Society of 
Endoscopic Surgery and new technologies (SICE), and the 
Spanish Association of Surgeons—HPB Section (AEC), 
developed the questionnaire using web-based and remote 
discussion, after identifying the components and topics to 
include.
Aim of the study
Since the clinical compliance with recommendations about 
AP is poor and the impact of implementing guidelines rec-
ommendations in biliary AP has not been well studied glob-
ally, we launched the MANCTRA-1 study with the aim to 
demonstrate areas where there is currently a sub-optimal 
implementation of current guidelines on biliary AP.
Moreover, we argue that during the COVID-19 pandemic, 
the tendency to disregard the guidelines recommendations 
has been more marked than usual, and we will try to find 
out if the care of AP patients during the COVID-19 pan-
demic resulted in a higher rate of adverse outcomes com-
pared to non-pandemic times due to the lack of compliance 
to guidelines.
Primary aim
To evaluate which items of the current AP guidelines, if 
disregarded, correlate with negative clinical outcomes 
according to the different clinical presentations of the 
disease.
Secondary aim
To assess the compliance of surgeons worldwide to the 
most up-to-date international guidelines on biliary AP.
To evaluate the medical and surgical practice in the 
management of biliary AP during the non-pandemic 
(2019) and pandemic COVID-19 periods (2020).
To investigate outcomes of patients with biliary AP 
treatment during the two study periods.
Primary outcome measures
In-hospital mortality: assessed by the number of 
patients deceased in hospital due to complications 
directly related to AP with biliary etiology during the 
non-pandemic period (2019) and the COVID-19 pan-
demic period (2020).
In-hospital morbidity: assessed by the number of AP 
patients with biliary etiology who experienced any type 
of AP-related complication during the hospital admis-
sion in 2019 (non-pandemic period) and 2020 (pan-
demic period).
Secondary outcome measures
Early definitive treatment rate in 2019 vs. 2020: defined 
as treatment in accordance with the current guidelines 
(cholecystectomy or ERCP with endoscopic sphincter-
otomy during the same hospital admission or within 
2 weeks of discharge).
30-Day hospital readmission rate in 2019 vs. 2020: 
defined as hospital readmission within 30 days from 
discharge for recurrent biliary AP while awaiting inter-
val cholecystectomy, or due to post-cholecystectomy 
complications.
Predictive factors of morbidity and mortality in patients 
with biliary AP.
The compliance of surgeons to the most up-to-date 
international guidelines on biliary AP will be assessed 
through the analysis of the following attitudes:
 Updates in Surgery
1 3
Use of scoring systems for the diagnosis and severity 
grading of biliary AP.
Use of lipase dosage (for the diagnosis) and C-reactive 
protein—CRP (for the severity grading) during the 
diagnostic workup.
Use of Ultrasound scan, CT scan, MRCP, and endo-
scopic Ultrasound scan (EUS) in the correct way and 
timing.
Use of early ERCP and sphincterotomy in case of chol-
angitis and/or choledocholithiasis.
Use of percutaneous and/or endoscopic drainage in case 
of infected pseudocyst or walled-off necrosis (WON).
Timing of surgical necrosectomy.
Timing of re-laparotomy in case of open abdomen strate-
gies.
Use of prophylactic antibiotics/antifungals in the first 
week.
Use of somatostatin analogs.
Use of early oral/enteral feeding.
Use of early definitive treatment strategies, including 
cholecystectomy and/or ERCP and sphincterotomy.
Study design
The MANCTRA-1 study is an international multicenter, ret-
rospective cohort study to assess the outcomes of patients 
admitted to hospital with a diagnosis of biliary AP and the 
compliance of surgeons worldwide to the most up-to-dated 
international guidelines on biliary AP. The study compares 
data collected in 2019 (pre-pandemic period) with those of 
2020 (COVID-19 pandemic period).
Study population
All consecutive adult patients admitted to the participating 
surgical departments with a clinical and radiological diag-
nosis of biliary AP (with and without concomitant cholecys-
titis) between 01/01/2019 and 31/12/2020 will be included 
in the study. Patient data will be retrospectively analyzed, 
and demographic characteristics, comorbidity status, clinical 
and radiological findings, treatment strategies, in-hospital 
morbidity, and mortality will be evaluated.
Inclusion criteria
Patients of both sexes, ≥ 16 years old, admitted to any of 
the participating general surgery departments, hepatopan-
creatobiliary (HPB) surgery departments, and/or internal 
medicine or gastroenterology departments for biliary AP in 
2019 and 2020.
Exclusion criteria
Patients with AP having an etiology other than gallstones; 
pregnant patients.
Study periods
The pre-pandemic period runs from 01/01/2019 to 
31/12/2019. The COVID-19 pandemic period is from 
01/01/2020 to 31/12/2020. Data will be entered in the data-
base from 01/04/2021 to 31/08/2021. Strategies to identify 
consecutive patients will include review of elective and 
emergency theater logbooks, review of handover sheets and 
ward lists, and review of institutional databases.
Sample size
Studies on biliary AP found a mortality rate of approxi-
mately 10%. Patients with biliary AP tend to have a higher 
mortality than patients with alcoholic pancreatitis. However, 
this rate has been falling over the last 2 decades as improve-
ments in supportive care have been introduced. In patients 
with severe disease (organ failure), accounting for about 20% 
of presentations, mortality is approximately 30%. This rate 
has not decreased in the past 10 years.
We estimate that a minimum of 200 patients per group 
(2019 vs. 2020) would yield a power of 0.80 (1-β) to estab-
lish whether changes in clinical care for patients with biliary 
AP during the COVID-19 pandemic has impacted on overall 
mortality using a one-sided significance α level of 0.05 (5%) 
with power sample size calculator (sealedenvelope.com).
Statistical analysis
The dichotomous variables will be expressed as numbers and 
percentages, while continuous variables will be expressed as 
mean and standard deviation (SD), or median and interquar-
tile range (IQR, minimum and maximum values). Student’s t 
test or ANOVA will be used for comparisons of continuous 
variables between groups. Chi-squared test or Fisher’s exact 
test, as appropriate, will be used for analysis of categorical 
data.
A propensity score model will be implemented consider-
ing the following variables as covariates: patient age, sex, 
Body Mass Index (BMI), Charlson’s comorbidity index, 
q-SOFA score, WSES sepsis score, BISAP (Bedside Index 
of Severity in Acute Pancreatitis) score, ASA score, Glas-
gow-Imrie score, Ranson’s score, and presence of concomi-
tant findings on admission (choledocholithiasis with com-
mon bile duct obstruction, cholangitis). Patients treated in 
2019 and 2020 will be matched using the “nearest neighbor 
matching,” based on the individual propensity score and 
with a 1:1 matching model with replacement.
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Planned investigations of subgroups will be carried out 
for different severity grades of the disease according to 
the revised Atlanta Classification [34], setting of acquisi-
tion of the pancreatitis (community acquired or hospital 
acquired), and hospital characteristics (Academic/Non-
Academic setting, performance factors related to hospital 
patient volume, access to hepatopancreatobiliary subspe-
cialty services, and admitting speciality);
Multiple regression model, including moderation and 
mediation analysis, will be used to investigate clinical var-
iables (independent) predictive of morbidity and mortality:
Non-compliance to AP practice guidelines regarding 
medical and antibiotic therapy, nutritional support, man-
agement of complications, endoscopic treatment, and tim-
ing of cholecystectomy;
COVID-19 status on admission;
Physical, laboratory, and radiologic variables.
Residual analysis will also be conducted to investigate 
the amount of information that cannot be explained by the 
model. Machine learning (ML) such as random forest and 
ANNs will also be used to investigate the information held 
within the predictor variables.
A value of P < 0.05 will be considered statistically 
significant.
Ethical aspects and publication policy
This is an international observational study; it will not 
attempt to change or modify the clinical practice of the par-
ticipating physicians. The study will meet and conform to 
the standards outlined in the Declaration of Helsinki and 
Good Epidemiological Practices.
Ethics Committee approval was obtained in Italy (Accept-
ance Code: Independent Ethics Committee of the Univer-
sity of Cagliari, Prot. PG/2021/7108) from the coordinating 
center.
National leads in other countries will oversee appropriate 
registration and study approval, which may include com-
pleting full ethical review depending on the local policy for 
observational and non-interventional studies. Local leads 
from the UK participating centers will be prompted to con-
sider using the HRA REC National Research Ethics Service 
decision tool (http:// www. hra- decis ionto ols. org. uk) to know 
whether a formal ethical approval is required to take part in 
the study.
The Local lead and two Collaborators from each center 
will be listed as Co-authors in the final publications. Data 
will be published as a pool from all participating surgical 
units [35], and published irrespective of findings. Results 
will be published on ClinicalTrials.Gov and each manuscript 
that is generated based on the registry will be disseminated 
to all participating centers before final publication.
Fig. 1  Chart showing global distribution of participating centers
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Data collection
National committees will lead the study in participating 
countries, with overall coordination provided by the study 
steering committee. The MANCTRA-1 study involves 
286 clinical centers from 51 countries worldwide to date 
(Fig. 1). In each center, the coordinator will collect epi-
demiological, clinical, and surgical data on a case report 
form (CRF) that will be completed by accessing a pro-
tected data system. The link for accessing the comple-
tion of the CRF will be sent via email to only one contact 
person (local lead) of each participating center (Suppl. 
Material Table 1). The database was developed by the 
MANCTRA-1 Steering Committee using web-based and 
remote discussion, after identifying the key components 
and topics to include. Seventeen clinical sections were 
identified, that included closed and open-ended questions. 
Online questions and response items in the Google Forms 
database are available by accessing the link https:// forms. 
gle/ PLZhf 73kGt NhhJE y7.
Data will be recorded contemporaneously on a dedi-
cated server that allows collaborators to enter and store 
data in a secure system (Google Form survey software, 
Google, Mountain View, California, USA) hosted and 
managed by the University of Cagliari, Italy. No patient 
identifiable data (name, date of birth, address, telephone 
number, etc.) will be recorded. A database will be gener-
ated in Excel for Mac, and final statistical analyses will be 
performed using R version 4.0.2 and SPSS V.22.
Due to its retrospective design, this observational study 
will not attempt to change or modify the laboratory or 
clinical practices of the participating physicians. Conse-
quently, informed consent will not be required.
Data completeness
Strategies to identify consecutive patients with biliary AP 
admitted at each participating center from 01/01/2019 to 
31/12/2019 will include: manual review of emergency hos-
pital admissions; electronic review of the hospital admis-
sions software with specific query for AP codes; manual 
or electronic review of handover sheets and ward lists; 
manual or electronic review of theater logbooks.
Following data collection, only data sets with > 95% 
data completeness will be accepted for pooled interna-
tional analyses. Centers who do not upload patients meet-
ing the eligibility criteria or with > 5% missing data points 
cannot be included in the study and local leads from those 
centers will be asked to complete the missing boxes with 
the requested data. Failure to meet these requirements will 
cause the exclusion from the publication list.
Discussion
Findings from previous studies about the compliance with 
AP guidelines support the view that publication only of 
nationally or internationally developed and approved guide-
lines is insufficient to modify the practice of non-specialists 
and raises the question of how best to spread guideline rec-
ommendations. Previous reports, including the one from 
France in 2012, have shown that major changes in biliary 
AP patients’ management were noticed since the French 
guidelines publication. In particular, after the publication 
of the mentioned guidelines, lipase levels were measured for 
establishing AP diagnosis by 99% (vs. 83% pre-guidelines), 
and a CT scan was performed at 48 h by 69% (vs. 29% pre-
guidelines) to evaluate AP severity. Antibiotic prophylaxis 
and enteral nutrition were proposed by 20% (vs. 57% pre-
guidelines) and 58% (vs. 25% pre-guidelines) for necrotizing 
AP [36].
In a recent multicenter international survey on the pat-
terns of early management of AP, Talukdar et al. demon-
strated that there is still non-compliance to practice guide-
lines in severity prediction, fluid therapy monitoring, use of 
antibiotics, and feeding modalities. Among the participating 
specialists who followed the guidelines, nearly 42% and 60% 
were actually non-compliant to feeding and antibiotic rec-
ommendations, respectively [24]. Moreover, there are sig-
nificant differences in behaviors regarding various aspects of 
fluid therapy, feeding, and antibiotic use between clinicians 
from academic and non-academic centers. A significantly 
higher proportion of clinicians from academic centers would 
use Ringer’s solution as the first fluid choice compared to 
non-academic practice groups (79.2% vs. 55.6%), whereas 
a significantly higher proportion of clinicians in the non-
academic setting would start antibiotics during the first week 
of illness based on the presence of necrosis on CT scan. 
Relevant differences in AP management also exist between 
the admitting specialists. The authors found that a signifi-
cantly higher proportion of physicians compared to surgeons 
(53.1% vs. 27.8%) opted to use SIRS criteria to assess sever-
ity, whereas a significantly higher proportion of surgeons 
compared to physicians would opt to use nasogastric tube 
(40.7% vs. 26.3%) [24]. Reasons for which we decided to 
plan investigations of subgroups basing on hospital charac-
teristics, performance factors related to hospital patient vol-
ume, the admitting specialty, and the availability of hepato-
pancreatobiliary subspecialty services.
Discrepancies in management and lack of compliance 
to guidelines had been reported earlier in different surveys 
from Europe and New Zealand [22–24]. Aly et al. showed in 
their survey that significant differences in survey assessment, 
indication, and timing of requesting CT scan and nutritional 
support existed between the practice of HPB specialists 
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and non-specialists [26]. A subsequent survey in 2012 that 
involved 51 surgical departments (nine academic hospitals 
and 42 non-academic hospitals) in Sweden also revealed a 
lack of early severity stratification and a difference in stand-
ard of care between different hospitals [25]. These studies 
emphasized on two relevant issues: the need for evidence-
based standardization of management of biliary AP, and 
the importance of a timely referral to a specialist unit for 
patients with severe AP and those with extensive necrotizing 
forms or with other complications who may require intensive 
therapy unit care, or interventional radiological, endoscopic, 
or surgical procedures. The management of severe cases 
of AP requires not only the availability of numerous spe-
cialty services (gastroenterology, surgery, critical care, and 
interventional radiology), but also the experience to coor-
dinate a multidisciplinary team. An analysis of the United 
States Nationwide Inpatient sample showed that treatment 
of patients with AP in high-volume centers resulted in a 
decreased risk of prolonged hospital stay and mortality [37, 
38]. According to the UK Party on Acute Pancreatitis, every 
hospital that receives acute admission should have a nomi-
nated multidisciplinary clinical team to manage all patients 
with AP. If the full range of specialists is not available in 
the receiving hospital, the nominated team should coordi-
nate local management where possible, and the referral to a 
specialist unit where appropriate. Moreover, in every hos-
pital, the nominated team should maintain regular audit of 
all patients with AP under a coordination at a regional level 
[14]. Similarly, the International Association of Pancreatol-
ogy (IAP) and the American Pancreatic Association (APA) 
stated that management in, or referral to, a specialist center 
is necessary for patients with severe AP and for those who 
may need interventional radiologic, endoscopic, or surgical 
operation. A specialist center in the management of AP is 
defined as a high-volume center with intensive-care facilities 
and with daily access to interventional radiology, interven-
tional endoscopy with EUS and ERCP assistance, as well as 
surgical expertise in managing necrotizing AP. A minimum 
of two specialists should be available in all field of expertise 
(interventional endoscopy, interventional radiology, critical 
care medicine, and surgery) to allow for minimum coverage 
[15].
On these premises, we have started the MANCTRA pro-
ject, a global research alliance aiming to improve the care 
of biliary AP worldwide. The MANCTRA-1 retrospective 
cohort study represents the first step of the project, and it has 
been launched to summarize the contemporary main areas of 
sub-optimal care due to the lack of compliance with current 
guidelines. Unlike the earlier studies that involved primarily 
surgeons within particular national societies, in the MANC-
TRA-1 study, we involved different healthcare specialists 
that handle patients with biliary AP. The results of the 
MANCTRA-1 study will be analyzed with the perspective 
to provide the basis for introducing a number of bundles in 
biliary AP patients’ management to be implemented during 
the next years. Following the introduction of the AP bundles 
in 2022, the MANCTRA-2 prospective international study 
will be launch in 2025 to assess the potential advancements 
for biliary AP patients’ care in those centers that have taken 
part in the project.
Conclusion
Biliary AP represents a therapeutic challenge and a signifi-
cant burden for the healthcare systems. Sub-optimal care 
of AP patients due to the lack of compliance with current 
guidelines is related with an increasing rate of adverse 
events. A global effort is necessary to improve biliary AP 
patients care. The MANCTRA-1 international retrospec-
tive cohort study will evaluate which items of the current 
AP guidelines, will correlate, if disregarded, with negative 
clinical outcomes according to the different clinical presen-
tations of the disease, ultimately aiming to introduce new 
improvement strategies for the care of patients suffering 
from biliary AP.
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